Experience with bortezomib for the treatment of patients with relapsed classical Hodgkin lymphoma
- 15 February 2006
- journal article
- Published by American Society of Hematology in Blood
- Vol. 107 (4), 1731a-1732
- https://doi.org/10.1182/blood-2005-09-3731
Abstract
No abstract availableKeywords
This publication has 5 references indexed in Scilit:
- Activity of selective fully human agonistic antibodies to the TRAIL death receptors TRAIL‐R1 and TRAIL‐R2 in primary and cultured lymphoma cells: induction of apoptosis and enhancement of doxorubicin‐ and bortezomib‐induced cell deathBritish Journal of Haematology, 2005
- Phase II Study of Proteasome Inhibitor Bortezomib in Relapsed or Refractory B-Cell Non-Hodgkin's LymphomaJournal of Clinical Oncology, 2005
- Phase II Clinical Experience With the Novel Proteasome Inhibitor Bortezomib in Patients With Indolent Non-Hodgkin's Lymphoma and Mantle Cell LymphomaJournal of Clinical Oncology, 2005
- Induction of Cell Cycle Arrest and Apoptosis by the Proteasome Inhibitor PS-341 in Hodgkin Disease Cell Lines Is Independent of Inhibitor of Nuclear Factor-κB Mutations or Activation of the CD30, CD40, and RANK ReceptorsClinical Cancer Research, 2004
- A Phase 2 Study of Bortezomib in Relapsed, Refractory MyelomaNew England Journal of Medicine, 2003